Our Innovation
What We Built
-
SYNCARDIA is a next-generation treatment designed to regenerate heart muscle after myocardial infarction (heart attack) by combining precision delivery, biological logic, and temporary gene expression.
-
SYNCARDIA restores heart function by converting scar-forming fibroblasts into contractile cardiomyocyte-like cells in the infarct border zone.
Epigenetic Priming (PHF7)
Epigenetic Priming (PHF7)
Opens chromatin at cardiac gene sites in fibroblasts, creating a timed 48-hour priming window before automatically degrading.
Cardiomyocyte Conversion (GMT)
Gata4, Mef2c, and Tbx5 transcription factors reprogram scar cells into beating cardiac-like muscle cells once chromatin is accessible.
Electrical Integration (Cx43)
Connexin-43 gap junctions synchronize new cells into the heart's electrical network only after full cardiac regeneration occurs.
Ultrasound - Guided LNP Delivery
Non-viral lipid nanoparticles delivered by IV, then precisely activated over the heart by focused ultrasound